When Covidien, now part of Medtronic (Dublin), bought superDimension in 2012 for $300 million, the company expected to sell the lung cancer diagnostic technology the old fashioned way. "Historically, we would have sold a product like this on features and benefits and relationships," Michael Tarnoff, VP and chief medical officer of the minimally invasive therapies group at Medtronic, told Medical Device Daily. "Today and beyond, we're looking to sell these things based on evidence." Read More
